• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Remote early detection of SARS-CoV-2 infections using a wearable-based algorithm: Results from the COVID-RED study, a prospective random

tetano

Editor, Senior Moderator
PLoS One


. 2025 Jun 5;20(6):e0325116.
doi: 10.1371/journal.pone.0325116. eCollection 2025. Remote early detection of SARS-CoV-2 infections using a wearable-based algorithm: Results from the COVID-RED study, a prospective randomised single-blinded crossover trial

Laura C Zwiers[SUP] 1 2 [/SUP], Timo B Brakenhoff[SUP] 1 [/SUP], Brianna M Goodale[SUP] 1 3 [/SUP], Duco Veen[SUP] 4 5 [/SUP], George S Downward[SUP] 2 6 [/SUP], Vladimir Kovacevic[SUP] 3 7 [/SUP], Andjela Markovic[SUP] 3 8 [/SUP], Marianna Mitratza[SUP] 2 [/SUP], Marcel van Willigen[SUP] 1 [/SUP], Billy Franks[SUP] 1 [/SUP], Janneke van de Wijgert[SUP] 9 [/SUP], Santiago Montes[SUP] 10 [/SUP], Serkan Korkmaz[SUP] 11 [/SUP], Jakob Kjellberg[SUP] 11 [/SUP], Lorenz Risch[SUP] 12 13 14 [/SUP], David Conen[SUP] 15 [/SUP], Martin Risch[SUP] 12 16 [/SUP], Kirsten Grossman[SUP] 12 13 [/SUP], Ornella C Weideli[SUP] 12 13 [/SUP], Theo Rispens[SUP] 17 18 [/SUP], Jon Bouwman[SUP] 1 [/SUP], Amos A Folarin[SUP] 19 20 21 [/SUP], Xi Bai[SUP] 19 [/SUP], Richard Dobson[SUP] 19 [/SUP], Maureen Cronin[SUP] 3 [/SUP], Diederick E Grobbee[SUP] 1 2 [/SUP]; COVID-RED consortium



Affiliations
Abstract

Background: Rapid and early detection of SARS-CoV-2 infections, especially during the pre- or asymptomatic phase, could aid in reducing virus spread. Physiological parameters measured by wearable devices can be efficiently analysed to provide early detection of infections. The COVID-19 Remote Early Detection (COVID-RED) trial investigated the use of a wearable device (Ava bracelet) for improved early detection of SARS-CoV-2 infections in real-time.
Trial design: Prospective, single-blinded, two-period, two-sequence, randomised controlled crossover trial.
Methods: Subjects wore a medical device and synced it with a mobile application in which they also reported symptoms. Subjects in the experimental condition received real-time infection indications based on an algorithm using both wearable device and self-reported symptom data, while subjects in the control arm received indications based on daily symptom-reporting only. Subjects were asked to get tested for SARS-CoV-2 when receiving an app-generated alert, and additionally underwent periodic SARS-CoV-2 serology testing. The overall and early detection performance of both algorithms was evaluated and compared using metrics such as sensitivity and specificity.
Results: A total of 17,825 subjects were randomised within the study. Subjects in the experimental condition received an alert significantly earlier than those in the control condition (median of 0 versus 7 days before a positive SARS-CoV-2 test). The experimental algorithm achieved high sensitivity (93.8-99.2%) but low specificity (0.8-4.2%) when detecting infections during a specified period, while the control algorithm achieved more moderate sensitivity (43.3-46.4%) and specificity (66.4-65.0%). When detecting infection on a given day, the experimental algorithm also achieved higher sensitivity compared to the control algorithm (45-52% versus 28-33%), but much lower specificity (38-50% versus 93-97%).
Conclusions: Our findings highlight the potential role of wearable devices in early detection of SARS-CoV-2. The experimental algorithm overestimated infections, but future iterations could finetune the algorithm to improve specificity and enable it to differentiate between respiratory illnesses.
Trial registration: Netherlands Trial Register number NL9320.


 
Back
Top Bottom